Related references
Note: Only part of the references are listed.2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD
Francesco Cosentino et al.
EUROPEAN HEART JOURNAL (2020)
2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
John B. Buse et al.
DIABETES CARE (2020)
Review of the cardiovascular safety of dipeptidyl peptidase-4 inhibitors and the clinical relevance of the CAROLINA trial
Marile Santamarina et al.
BMC CARDIOVASCULAR DISORDERS (2019)
Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes
Thwe Htay et al.
CURRENT CARDIOLOGY REPORTS (2019)
Cardiovascular Disease in Patients with Type 2 Diabetes and in Patients Starting Empagliflozin Treatment: Nationwide Survey
Bjorn Eliasson et al.
DIABETES THERAPY (2019)
Sex differences in the burden of type 2 diabetes and cardiovascular risk across the life course
Amy G. Huebschmann et al.
DIABETOLOGIA (2019)
Cost analysis of type 2 diabetes mellitus treatment in economically developed countries
Sara Ramzan et al.
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH (2019)
Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
Soren L. Kristensen et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
Thomas A. Zelniker et al.
LANCET (2019)
Economic Burden of Cardiovascular Disease in Type 2 Diabetes: A Systematic Review
Thomas R. Einarson et al.
VALUE IN HEALTH (2018)
Excess risk of hospitalisation for heart failure among people with type 2 diabetes
Annika Rosengren et al.
DIABETOLOGIA (2018)
Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Aidin Rawshani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes
Aidin Rawshani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Healthcare utilization and costs following newly diagnosed type-2 diabetes in Sweden: A follow-up of 38,956 patients in a clinical practice setting
Ugne Sabale et al.
PRIMARY CARE DIABETES (2015)
Annual Medical Costs of Swedish Patients with Type 2 Diabetes Before and After Insulin Initiation
Christin Bexelius et al.
DIABETES THERAPY (2013)
Age-specific direct healthcare costs attributable to diabetes in a Swedish population: a register-based analysis
A. -B. Wirehn et al.
DIABETIC MEDICINE (2008)
Resource use and costs of type 2 diabetes in Sweden -: estimates from population-based register data
A. Ringborg et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2008)
Direct medical costs for patients with type 2 diabetes in Sweden
F Henriksson et al.
JOURNAL OF INTERNAL MEDICINE (2000)
Share Paper
